What is a New Therapy for Respiratory Syncytial Virus infection?

Abstract:

Human respiratory syncytial virus (RSV) is a single-strand RNA virus of the Paramyxoviridae family in the order of Mononegavirales which causes acute lower respiratory tract infections (ALRTI) leading to hospitalization and mortality in young children. Respiratory syncytial virus (RSV) is the main cause of pediatric acute lower respiratory tract infection (ALRTI) globally. The World Health Organization estimates that RSV accounts worldwide for more than 60% of acute respiratory infections in children and more than 80% in infants younger than 1 year, especially at the peak of viral season. An estimated  33 million children under 5 years were diagnosed with new episodes of RSV-associated ALRTI with at least 3.2-3.4 million admitted episodes due to severe RSV-associated ALRTI. Approximately 66,000-199,000 of them died from RSV and 99% of these deaths occurred in developing countries. This review addresses the new therapies investigated in RVS patients. Furthermore, their essential antiviral action and specific classes of clinically approved drugs have been clarified. These clinical trial outcomes can enhance our understanding of the antiviral activities of these drugs.